6/14
04:44 pm
cstl
Castle Biosciences' Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner [Yahoo! Finance]
Low
Report
Castle Biosciences' Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner [Yahoo! Finance]
6/14
04:30 pm
cstl
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
Low
Report
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
6/13
03:56 pm
cstl
Flinn Foundation-Sponsored Study Identifies Three Bioscience Growth Areas to Advance Innovation and Economic Growth in Greater Phoenix [Yahoo! Finance]
Neutral
Report
Flinn Foundation-Sponsored Study Identifies Three Bioscience Growth Areas to Advance Innovation and Economic Growth in Greater Phoenix [Yahoo! Finance]
6/13
12:06 pm
cstl
Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
5/30
04:50 pm
cstl
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance [Yahoo! F
Medium
Report
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance [Yahoo! F
5/30
04:30 pm
cstl
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
Medium
Report
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
5/29
04:44 pm
cstl
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis [Yahoo! Finance]
Low
Report
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis [Yahoo! Finance]
5/29
04:30 pm
cstl
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
Low
Report
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
5/20
12:09 pm
cstl
American Society for Gastroenterology and Endoscopy Launches Artificial Intelligence Institute at Digestive Disease Week [Yahoo! Finance]
Low
Report
American Society for Gastroenterology and Endoscopy Launches Artificial Intelligence Institute at Digestive Disease Week [Yahoo! Finance]
5/15
07:12 am
cstl
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference [Yahoo! Finance]
Low
Report
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference [Yahoo! Finance]
5/15
07:00 am
cstl
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
Low
Report
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
5/14
07:08 am
cstl
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024 [Yahoo! Finance]
Low
Report
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024 [Yahoo! Finance]
5/14
07:00 am
cstl
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
Low
Report
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
5/10
07:03 am
cstl
Castle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution" [Yahoo! Finance]
Low
Report
Castle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution" [Yahoo! Finance]
5/10
07:00 am
cstl
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
Low
Report
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
5/8
04:46 pm
cstl
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result [Yahoo! Finance]
Medium
Report
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result [Yahoo! Finance]
5/8
04:30 pm
cstl
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
Medium
Report
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
5/6
10:48 am
cstl
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
Low
Report
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
5/5
09:28 am
cstl
Earnings Beat: Castle Biosciences, Inc. (NASDAQ:CSTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts [Yahoo! Finance]
Low
Report
Earnings Beat: Castle Biosciences, Inc. (NASDAQ:CSTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts [Yahoo! Finance]
5/5
08:42 am
cstl
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/3
08:07 am
cstl
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $33.00 to $34.00. They now have an "outperform" rating on the stock.
Medium
Report
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $33.00 to $34.00. They now have an "outperform" rating on the stock.
5/3
07:00 am
cstl
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
Medium
Report
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
5/2
07:52 pm
cstl
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
5/2
04:44 pm
cstl
Castle Biosciences Reports First Quarter 2024 Results [Yahoo! Finance]
Medium
Report
Castle Biosciences Reports First Quarter 2024 Results [Yahoo! Finance]
5/2
04:05 pm
cstl
Castle Biosciences Reports First Quarter 2024 Results
Medium
Report
Castle Biosciences Reports First Quarter 2024 Results